ALBERTA BLUE CROSS®

ANTIVIRALS FOR CHRONIC HEPATITIS C SPECIAL AUTHORIZATION REQUEST FORM

Please complete all required sections to allow your request to be processed.

Patients may or may not meet eligibility requirements as established by Alberta government-sponsored drug programs.

PATIENT INFORMATION			COVERAGE TYPE
PATIENT LAST NAME	FIRST NAME	INITIAL	☐ Alberta Blue Cross ☐ Alberta Human Services ☐ Other
BIRTH DATE (YYYY-MM-DD)	ALBERTA PERSONAL HEALTH NUMBER		
STREET ADDRESS	CITY / PROV / POSTAL CODE		ID/CLIENT/COVERAGE NUMBER

PRESCRIBER INFORMATION		
PRESCRIBER LAST NAME / FIRST NAME / INITIAL	PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION ☐ CPSA ☐ ACO ☐ CARNA ☐ ADA+C ☐ ACP ☐ Other	REGISTRATION NUMBER
STREET ADDRESS		
CITY, PROVINCE	PHONE	FAX
POSTAL CODE	FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED	

1) Indicate the requested drug regimen and the patient's Hepatitis C Virus (HCV) Genotype

*Drug regimen requested	Corresponding HCV genotype
☐ Elbasvir/grazoprevir (e.g. Zepatier) +/- ribavirin (e.g. Ibavyr)	☐ Genotype 1 → Specify subtype ________ ☐ Genotype 4
☐ Glecaprevir/pibrentasvir (e.g. Maviret)	Genotype ________ (optional if treatment naïve)
☐ Sofosbuvir (e.g. Sovaldi) + ribavirin (e.g. Ibavyr)	☐ Genotype 2 ☐ Genotype 3
☐ Sofosbuvir/ledipasvir (e.g. Harvoni) +/- ribavirin (e.g. Ibavyr)	☐ Genotype 1
☐ Sofosbuvir/velpatasvir (e.g. Epclusa) +/- ribavirin (e.g. Ibavyr)	Genotype not required
☐ Sofosbuvir/velpatasvir/voxilaprevir (e.g. Vosevi)	Genotype ________ (optional if prior NS5A inhibitor)

*Duration of therapy and coverage of ribavirin in combination with the selected drug regimen will be approved according to criteria specified in the *Alberta Drug Benefit List.*

2) Does the patient have a quantitative HCV RNA value within six months of this request?

☐ **Yes** → Provide test date (YYYY-MM-DD) ____________________ ☐ **No** ☐ **Not tested**

3) Does the patient have cirrhosis?

☐ **Yes, compensated cirrhosis with Child-Turcotte-Pugh A** (i.e. score five to six)
☐ **Yes, decompensated cirrhosis with Child-Turcotte-Pugh B or C** (i.e. score seven or above)
☐ **No**

4) For sofosbuvir/ledipasvir (e.g. Harvoni) requests ONLY, if applicable:
Is treatment requested post liver transplant? ☐ **Yes** ☐ **No**

5) Has the patient previously been treated with an HCV antiviral drug regimen?

☐ **No,** the patient is treatment-naïve
☐ **Yes** → Specify drug regimen previously used ____________________
→ Specify the patient's response
☐ failure ☐ intolerance ☐ relapse
☐ other; specify ____________________

6) If the patient is currently on the requested drug regimen, please indicate start date (YYYY-MM-DD) ____________________

7) Indicate the name of the specialist consulted, where applicable ____________________

Additional information relating to request

PRESCRIBER'S SIGNATURE	DATE (YYYY-MM-DD)	Please forward this request to **Alberta Blue Cross, Clinical Drug Services** **10009 108 Street NW, Edmonton, Alberta T5J 3C5** FAX: **780-498-8384** in Edmonton • **1-877-828-4106** toll free all other areas

The information on this form is being collected and pursuant to sections 20, 21 and 22 of the Health Information Act, and sections 33 and 34 of the Freedom of Information and Protection of Privacy Act, for the purposes of determining or verifying eligibility to participate in a program or receive a benefit, product or health service. If you have any questions regarding the collection or use of this information, please contact an Alberta Blue Cross privacy matters representative toll-free at 1-855-498-7302 or write to Privacy Matters, Alberta Blue Cross, 10009 108 Street, Edmonton AB T5J 3C5.
®*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ®† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 60022 (2022/04)